# lung adenocarcinoma (LUAD) - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 1
- Task type: PROGNOSIS
- Tissue / sample source: lung adenocarcinoma tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: a2c9355177479f23c6c81afe1b39ba697ac131cc344bb83120b98e2c6bbfee49
- Response HTTP status: 200
- Prompt tokens: 3407
- Completion tokens: 26276
- Reasoning tokens: 
- Total tokens: 29683
- API requests reported: 
- Elapsed seconds: 421.432
- Final benchmark system: raw; file rank 1/5; original repeat 1; model vendor: DeepSeek

---
## Important initial data-quality caveat

A large fraction of the statistically extreme signals in this table are not plausibly interpretable as stable biological effects.

Genes such as `RBMY1F`, `RBMY2AP`, `TTTY4C`, `CDY10P`, `USP9YP3`, `FAM9A`, `TEX13A`, `Y_RNA`, `RNY1P3`, many `RP11/CTD/CTC` intergenic lncRNAs, mitochondrial/pseudogene-derived transcripts (`MTND1P1`, `ATP5PBP2`, `DIMT1P1`, `HMGN2P39`), and `UNMAPPED_ENSEMBL` transcripts show identical or near-identical hazard ratios of ~5.18e21, ~1.9e-22, or similarly extreme values with `P = 0` and `FDR = 0`.

This pattern is characteristic of **quasi-complete separation** or **zero-inflated expression**: if a gene is expressed in only a very small subset of patients, and that subset happens to correlate with survival events, Cox models can produce enormous, unstable HR estimates. Many of these genes are Y-chromosome-linked, pseudogenes, or poorly annotated transcripts. They may reflect sex, alignment artifacts, tumor purity, or extremely rare expression rather than true LUAD biology.

Therefore, the biological interpretation below is based primarily on genes with **plausible HRs** and significant FDRs, in roughly the `HR = 0.7–1.5` range.

---

## 1. Overall biological interpretation

Within the credible signal, the major theme is that **high expression of genes involved in transcriptional/developmental reprogramming, altered WNT signaling, and cytoskeletal/integrin/cell-surface remodeling is associated with worse overall survival** in LUAD.

More specifically:

- Several genes point toward **aberrant reactivation of developmental/homeobox transcription factors** (`PITX3`, `VAX1`) and **transcriptional corepressor activity** (`TLE1`).
- `DKK1`, a WNT pathway inhibitor but also a WNT-induced feedback target, is associated with poor prognosis, suggesting altered WNT signaling rather than simple WNT activation or suppression.
- A cluster of genes related to **Rho GTPase signaling, integrin biology, actin dynamics, glycosylation, and epithelial cytoskeletal remodeling** (`RHOF`, `RGS20`, `ITGB1-DT`, `FUT4`, `KRT6A`, `LDLRAD3`) points toward an invasive, pro-migratory tumor phenotype.
- Several long noncoding RNAs (`LINC01312`, `LINC02178`, `LINC01910`, `LINC02323`, `LINC02802`, `LINC00707`) are consistently associated with worse survival, while `CRNDE` is protective in this dataset, a direction that conflicts with much of the published oncogenic literature for CRNDE and therefore should be interpreted cautiously.

No coherent protective biological program emerges. The main protective signals are either pseudogenes (`RBMXP1`, `CMAHP`) or `CRNDE`, and they are more likely to reflect technical, cell-composition, or context-dependent effects than a unified tumor-suppressive program.

---

## 2. Core biological programs

### Program 1: Developmental/WNT transcriptional reprogramming

- **Direction/prognostic association:** High expression associated with worse OS.
- **Supporting genes:** `DKK1`, `TLE1`, `PITX3`, `VAX1`
- **Closest pathway:** KEGG `hsa04310` Wnt signaling pathway; KEGG `hsa05202` Transcriptional misregulation in cancer.
- **Why these genes together:**  
  `PITX3` and `VAX1` are homeodomain transcription factors that are normally restricted largely to developmental tissues such as the midbrain, lens, and forebrain. Their high expression in LUAD is unusual and suggests aberrant activation of developmental transcriptional programs. `TLE1` encodes a Groucho-family transcriptional corepressor that modulates WNT and other developmental signaling outputs. `DKK1` is a secreted WNT inhibitor, but it is also a transcriptional target of WNT signaling, so high `DKK1` can mark an active WNT-response program or noncanonical WNT activation. The collective signal is therefore best described as **aberrant transcriptional/developmental reprogramming with altered WNT signaling equilibrium**, not as a simple on/off WNT effect.
- **Strength and limitations:**  
  Multiple genes with independent roles converge on the same broad theme, which increases confidence. However, this is not a formal pathway-enrichment result, `PITX3` and `VAX1` are not established LUAD oncogenes, and the current data cannot show whether these genes are expressed in malignant cells or in stromal/immune cells.

---

### Program 2: Rho/integrin/cytoskeletal and cell-surface remodeling

- **Direction/prognostic association:** High expression associated with worse OS.
- **Supporting genes:** `RHOF`, `RGS20`, `ITGB1-DT`, `FUT4`, `KRT6A`, `LDLRAD3`
- **Closest pathway:** KEGG `hsa04810` Regulation of actin cytoskeleton; Reactome `R-HSA-194840` Rho GTPase cycle; Reactome integrin cell-surface interactions.
- **Why these genes together:**  
  `RHOF` is a Rho-family GTPase involved in filopodia formation and actin dynamics. `RGS20` is a regulator of G-protein signaling that can influence GPCR-driven migration. `ITGB1-DT` is a divergent lncRNA at the `ITGB1` locus and is plausibly linked to regulation of integrin beta-1 expression or function, although this is not proven. `FUT4` encodes an alpha-1,3-fucosyltransferase that modifies cell-surface glycans, including adhesion receptors, and has been linked to cancer stemness and invasion. `KRT6A` encodes a keratin associated with basal/squamous-like epithelial remodeling and wound-related phenotypes. `LDLRAD3` is a cell-surface LDL-receptor-family member implicated in receptor-mediated signaling and cancer progression. Together, these genes suggest a tumor phenotype with **enhanced cytoskeletal plasticity, cell-matrix interaction, and invasive potential**.
- **Strength and limitations:**  
  This program is supported by several independent genes with concordant risk direction. The major limitation is that these genes do not all belong to one well-defined pathway, and `ITGB1-DT` function in LUAD is currently speculative.

---

### Program 3: Long noncoding RNA prognostic signal

- **Direction/prognostic association:** Mostly risk-associated; `CRNDE` is protective in this dataset.
- **Supporting genes:** `LINC01312`, `LINC02178`, `LINC01910`, `LINC02323`, `LINC02802`, `LINC00707`; protective: `CRNDE`
- **Closest pathway:** Not applicable. Most of these lncRNAs have no curated pathway annotation.
- **Why these genes together:**  
  Multiple poorly characterized LINC-family transcripts are independently associated with worse OS. This statistical consistency suggests they may represent a coordinated transcriptional signature, but the underlying biology is unknown. Some may act as cis-regulators of neighboring genes, while others may be markers of broader regulatory state changes. `CRNDE` is a well-known oncogenic lncRNA in many cancers, so its protective direction here is surprising and should not be accepted at face value without external validation and cell-type interrogation.
- **Strength and limitations:**  
  The consistency of the risk direction is notable. However, lncRNA expression is often highly collinear with nearby genes, cell composition, or technical artifacts, and there is no functional evidence in this dataset.

---

## 3. Key genes and interaction modules

### 1. `DKK1`
- **Statistic:** HR = 1.48, P = 4.27e-10, FDR = 3.55e-7.
- **Role:** Secreted WNT inhibitor and WNT-response gene. High expression may mark active WNT signaling or noncanonical WNT-related biology in LUAD.
- **Gene-gene relationship:** No direct physical interaction is claimed. Its relationship to `TLE1` is best described as **pathway co-membership** in WNT signaling.

### 2. `TLE1`
- **Statistic:** HR = 1.48, P = 3.20e-8, FDR = 2.46e-5.
- **Role:** Transcriptional corepressor in the Groucho/TLE family. It can repress WNT target genes and other differentiation-associated transcriptional programs.
- **Gene-gene relationship:** With `DKK1`, pathway co-membership in WNT signaling; with `PITX3`/`VAX1`, a possible regulatory/functional convergence in transcriptional reprogramming, but no direct interaction is established.

### 3. `PITX3` + `VAX1`
- **Statistics:** `PITX3` HR = 1.43, FDR = 3.49e-11; `VAX1` HR = 1.33, FDR = 9.25e-6.
- **Role:** Homeodomain transcription factors involved in developmental patterning. Their high expression in LUAD may reflect aberrant lineage plasticity or a stem-like/dedifferentiated state.
- **Gene-gene relationship:** They share **pathway co-membership** in developmental transcriptional programs, particularly anterior/eye/brain development. There is no evidence of direct physical interaction from this dataset.

### 4. `RHOF` + `RGS20` + `ITGB1-DT`
- **Statistics:** `RHOF` HR = 1.40; `RGS20` HR = 1.35; `ITGB1-DT` HR = 1.30.
- **Role:** `RHOF` regulates actin dynamics; `RGS20` links GPCR signaling to intracellular migration pathways; `ITGB1-DT` is a candidate cis-regulatory lncRNA for integrin beta-1.
- **Gene-gene relationship:** **Indirect/putative.** No direct physical interaction is supported by the current data. The relationship is best described as functional convergence on cell migration/adhesion, with `ITGB1-DT` potentially regulating `ITGB1` expression.

### 5. `FUT4` + `LDLRAD3`
- **Statistics:** `FUT4` HR = 1.40; `LDLRAD3` HR = 1.42.
- **Role:** `FUT4` mediates fucosylation of cell-surface glycans, including Lewis X/SSEA-1 antigens. `LDLRAD3` is a cell-surface receptor implicated in cancer-associated signaling.
- **Gene-gene relationship:** **Indirect/putative**, through cell-surface remodeling and receptor-mediated signaling. No direct interaction is established.

### 6. `KRT6A`
- **Statistic:** HR = 1.39, FDR = 2.78e-4.
- **Role:** Keratin 6A, an intermediate filament protein associated with basal-like or squamous-like epithelial states and tissue remodeling. In LUAD, high `KRT6A` could mark a histologically or molecularly aggressive tumor subtype.
- **Gene-gene relationship:** No direct interaction is proposed. It may be co-expressed with other risk genes because of shared tumor subtype or cell-state programs.

### 7. Risk-associated LINC RNA module
- **Genes/statistics:** `LINC01312` HR = 1.36; `LINC02178` HR = 1.30; `LINC01910` HR = 1.31; `LINC02323` HR = 1.37; `LINC02802` HR = 1.33; `LINC00707` HR = 1.32.
- **Role:** Unknown. They may represent a coordinated lncRNA expression program associated with aggressive LUAD.
- **Gene-gene relationship:** Best described as **co-expression / statistical co-association** from the same survival model. No regulatory or physical interaction evidence is available.

### 8. `CRNDE`
- **Statistic:** HR = 0.72, FDR = 1.03e-4.
- **Role:** Protective in this dataset. `CRNDE` is widely reported as an oncogenic lncRNA in other cancers, including lung cancer, so this direction is surprising and could reflect a different transcript isoform, cell-composition effect, or confounding.
- **Gene-gene relationship:** No direct interaction is proposed.

### 9. Sparse-expression artifact cluster
- **Genes:** `RBMY1F`, `RBMY2AP`, `TTTY4C`, `CDY10P`, `USP9YP3`, `TEX13A`, `FAM9A`, `Y_RNA`, `RNY1P3`, `TCP10L3`, `MTND1P1`, `DIMT1P1`, `ATP5PBP2`, many `RP11/CTD/CTC` transcripts, and `UNMAPPED_ENSEMBL` genes.
- **Role:** Not a biological module. The shared extreme HRs and `P = 0` values indicate unstable statistical fits, likely due to zero-inflated expression, sex-chromosome effects, low tumor purity, or alignment artifacts.
- **Gene-gene relationship:** They share a **technical artifact relationship**, not a biological interaction.

---

## 4. Validation priorities

### Priority 1: Technical artifact check and data cleaning
- **Classification:** Confounding or composition check.
- **Why:** Many top-ranked genes have implausible HRs, identical extreme values, and FDR = 0. If interpreted biologically, they would dominate the result and mislead downstream work.
- **Current evidence:** The table itself contains the extreme HR cluster.
- **External evidence:** Quasi-complete separation is well known in Cox regression with low-expression genes; Y-linked genes can simply reflect patient sex.
- **Next step:** Filter genes by minimum expression and percent of samples with non-zero counts; refit with Firth penalized Cox regression; stratify by sex; remove multi-mapping/unmapped transcripts.
- **Conclusion status:** Insufficient evidence. The extreme associations should not be considered biological until resolved.

---

### Priority 2: Independent cohort replication of moderate-risk genes
- **Classification:** Biomarker.
- **Why:** The biologically plausible genes have modest HRs and significant FDRs, but none are validated in an independent LUAD cohort.
- **Current evidence:** Multiple genes in the HR 1.3–1.5 range.
- **External evidence:** Some genes, such as `DKK1`, `KRT6A`, and `FUT4`, have prior cancer literature support, but many of the LINC RNAs do not.
- **Next step:** Test the same genes in TCGA-LUAD or independent GEO cohorts with multivariable Cox models adjusted for age, sex, stage, smoking, and treatment.
- **Conclusion status:** Supported hypothesis, not established biomarker.

---

### Priority 3: Functional validation of the developmental/WNT transcriptional module
- **Classification:** Mechanistic hypothesis.
- **Why:** `DKK1`, `TLE1`, `PITX3`, and `VAX1` point toward a potentially targetable biology involving cell-fate control and WNT signaling.
- **Current evidence:** Prognostic association only; no causal or mechanistic data.
- **External evidence:** WNT and developmental transcription factor programs are implicated in lung cancer plasticity, but `PITX3` and `VAX1` are not established LUAD drivers.
- **Next step:** CRISPR perturbation in LUAD cell lines; measure WNT reporter activity, differentiation/stemness markers, proliferation, migration, and in vivo tumor growth.
- **Conclusion status:** Exploratory hypothesis.

---

### Priority 4: Test the Rho/integrin/glycosylation invasion model
- **Classification:** Interaction / network hypothesis.
- **Why:** `RHOF`, `RGS20`, `ITGB1-DT`, `FUT4`, `LDLRAD3`, and `KRT6A` collectively suggest an invasive, adhesive, cytoskeletally active phenotype.
- **Current evidence:** Concordant risk direction among several independent genes.
- **External evidence:** Rho GTPases, integrins, and fucosyltransferases are known to promote invasion in multiple cancers. `ITGB1-DT` specifically is understudied.
- **Next step:** Test whether `ITGB1-DT` regulates `ITGB1` expression; perform migration/invasion assays after perturbation of `RHOF`, `FUT4`, or the putative `ITGB1-DT/ITGB1` axis; use glycosylation profiling if `FUT4` is studied.
- **Conclusion status:** Exploratory hypothesis.

---

### Priority 5: Resolve the protective `CRNDE` association and cell-composition issue
- **Classification:** Confounding or composition check.
- **Why:** `CRNDE` is protective here but is generally described as oncogenic in other cancers. This discrepancy may be due to stromal/immune expression, isoform usage, or confounding.
- **Current evidence:** `CRNDE` HR = 0.72 in this dataset.
- **External evidence:** Mixed/largely conflicting literature; many studies report `CRNDE` as an oncogene.
- **Next step:** Single-cell RNA-seq or spatial transcriptomics to determine which cells express `CRNDE`; use deconvolution to test whether the survival association is mediated by immune or stromal content; validate in an independent cohort.
- **Conclusion status:** Insufficient evidence / exploratory.

---

## 5. Evidence grounding

The interpretation relies on different evidence types, with different levels of independence:

- **Direct evidence from the input dataset:** HR, P value, and FDR for each gene. This is the only statistical evidence source. It establishes associations, not mechanisms.
- **Pathway/ontology evidence:** KEGG and Reactome annotations for WNT signaling, regulation of actin cytoskeleton, and Rho GTPase signaling. This is independent in origin but is annotation-based, not direct experimental evidence from this dataset.
- **Protein interaction or regulatory evidence:** No direct physical interaction data are provided. Statements about `TLE1` as a corepressor, `DKK1` as a WNT ligand, or `ITGB1-DT` as a putative cis-regulator are based on external knowledge, not on interactions detected here.
- **Disease-association evidence:** Some genes, including `DKK1`, `KRT6A`, `FUT4`, and `CRNDE`, have prior cancer literature associations. This is external evidence, but it overlaps with pathway annotations because both derive from prior functional studies.
- **Expression/tissue-specific evidence:** `PITX3` and `VAX1` are normally developmentally restricted; `KRT6A` marks basal/squamous-like epithelial states; Y-linked genes are sex-specific. These are useful context clues but are not direct proof of cell-type origin in this dataset.
- **Genetic/clinical evidence:** None is provided. No age, sex, stage, treatment, smoking, or tumor purity data are included.
- **Drug/therapeutic evidence:** None is provided. No drug-target conclusion can be drawn.

Important: the input table is **one statistical source**. Pathway and literature evidence can support biological plausibility, but they are not independent validation of the survival associations.

---

## 6. Limitations and alternative explanations

### 1. Sparse-expression and quasi-separation artifacts
Many genes with extreme HRs are likely artifacts of zero-inflated expression. This is the single most important limitation. It can be addressed by strict expression filters, penalized Cox regression, and sex-stratified analysis.

### 2. Lack of clinical covariate adjustment
The HRs may be confounded by age, sex, stage, smoking history, or treatment. For example, Y-chromosome-linked genes may simply mark male sex, which itself can be associated with OS in LUAD. Multivariable models and external clinical cohorts are essential.

### 3. Bulk tumor tissue and cell-composition effects
The tissue is whole LUAD tumor tissue, not purified malignant cells. Signals from genes such as `KRT6A`, `CRNDE`, or even `TLE1` may reflect stromal, immune, or normal epithelial cell content rather than cancer-cell biology. Single-cell RNA-seq, IHC, or deconvolution could distinguish these possibilities.

### 4. Histologic and molecular subtype confounding
LUAD is heterogeneous. Genes such as `KRT6A` and `FUT4` may mark particular histologic or molecular subtypes with different baseline prognoses. The associations may therefore reflect subtype identity rather than independent gene effects.

### 5. Single-cohort, multiple-testing, and pathway-annotation uncertainty
No independent validation cohort is included. Many genes are co-expressed, so their HRs are not independent. In addition, the "pathways" proposed here are inferred from gene function, not from a formal enrichment analysis, and should not be over-interpreted.

---

### Bottom line

The statistically plausible signal in this LUAD prognostic dataset supports a hypothesis that **developmental/WNT transcriptional reprogramming and cytoskeletal/integrin/cell-surface remodeling are associated with worse overall survival**. The many extreme-HR genes, especially pseudogenes and Y-linked transcripts, should be treated as technical artifacts until proven otherwise. No causal conclusions are warranted from the current data alone.
